A comparison of Symbicort [Budesonide/formoterol] single inhaler therapy (Symbicort turbuhaler 160/4.5mg, 1 inhalation b.i.d. plus as needed) and conventional best practice [antiasthmatics] for the treatment of persistent asthma in adults a -26-week, randomized, open-label, parallel-group, multicentre study

Trial Profile

A comparison of Symbicort [Budesonide/formoterol] single inhaler therapy (Symbicort turbuhaler 160/4.5mg, 1 inhalation b.i.d. plus as needed) and conventional best practice [antiasthmatics] for the treatment of persistent asthma in adults a -26-week, randomized, open-label, parallel-group, multicentre study

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Aug 2012

At a glance

  • Drugs Antiasthmatics; Budesonide/formoterol
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms PASSION
  • Most Recent Events

    • 29 Dec 2008 Actual end date (1 Sep 2008) added as reported by ClinicalTrials.gov.
    • 21 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top